BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Vogl UM, Zehetgruber H, Dominkus M, Hejna M, Zielinski CC, Haitel A, Schmidinger M. Prognostic factors in metastatic renal cell carcinoma: metastasectomy as independent prognostic variable. Br J Cancer. 2006;95:691-698. [PMID: 16940978 DOI: 10.1038/sj.bjc.6603327] [Cited by in Crossref: 77] [Cited by in F6Publishing: 67] [Article Influence: 4.8] [Reference Citation Analysis]
Number Citing Articles
1 Wong AS, Chong K, Heng C, Consigliere DT, Esuvaranathan K, Toh K, Chuah B, Lim R, Tan J. Debulking nephrectomy followed by a “watch and wait” approach in metastatic renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations 2009;27:149-54. [DOI: 10.1016/j.urolonc.2007.10.017] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.2] [Reference Citation Analysis]
2 Ganini C, Rovereto B, Porta C. Surgery and target agents for renal cell carcinoma treatment: the path between proper interaction. Urologia 2011;78 Suppl 18:9-15. [PMID: 22081423 DOI: 10.5301/RU.2011.8769] [Reference Citation Analysis]
3 Staderini F, Cianchi F, Badii B, Skalamera I, Fiorenza G, Foppa C, Qirici E, Perigli G. A unique presentation of a renal clear cell carcinoma with atypical metastases. Int J Surg Case Rep 2015;11:29-32. [PMID: 25911241 DOI: 10.1016/j.ijscr.2015.03.009] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
4 Belldegrun AS, Klatte T, Shuch B, LaRochelle JC, Miller DC, Said JW, Riggs SB, Zomorodian N, Kabbinavar FF, Dekernion JB, Pantuck AJ. Cancer-specific survival outcomes among patients treated during the cytokine era of kidney cancer (1989-2005): a benchmark for emerging targeted cancer therapies. Cancer 2008;113:2457-63. [PMID: 18823034 DOI: 10.1002/cncr.23851] [Cited by in Crossref: 63] [Cited by in F6Publishing: 60] [Article Influence: 4.5] [Reference Citation Analysis]
5 Dutcher JP, Flippot R, Fallah J, Escudier B. On the Shoulders of Giants: The Evolution of Renal Cell Carcinoma Treatment-Cytokines, Targeted Therapy, and Immunotherapy. Am Soc Clin Oncol Educ Book 2020;40:1-18. [PMID: 32243201 DOI: 10.1200/EDBK_280817] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
6 Pua BB, Thornton RH, Solomon SB. Ablation of pulmonary malignancy: current status. J Vasc Interv Radiol 2010;21:S223-32. [PMID: 20656232 DOI: 10.1016/j.jvir.2010.01.049] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 2.0] [Reference Citation Analysis]
7 Tatokoro M, Saito K, Iimura Y, Fujii Y, Kawakami S, Kihara K. Prognostic Impact of Postoperative C-Reactive Protein Level in Patients With Metastatic Renal Cell Carcinoma Undergoing Cytoreductive Nephrectomy. Journal of Urology 2008;180:515-9. [DOI: 10.1016/j.juro.2008.04.025] [Cited by in Crossref: 48] [Cited by in F6Publishing: 47] [Article Influence: 3.4] [Reference Citation Analysis]
8 Shinohara N, Abe T. Prognostic factors and risk classifications for patients with metastatic renal cell carcinoma. Int J Urol 2015;22:888-97. [DOI: 10.1111/iju.12858] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 2.9] [Reference Citation Analysis]
9 Życzkowski M, Rajwa P, Burzyński B, Gaździk M, Florczyk I, Slabon-Turska M, Paradysz A. Neutrophil-to-mean platelet volume ratio as a new predictor for overall and cancer-specific survival in patients with localized clear cell renal cell carcinoma. Arch Med Sci 2020;16:1072-7. [PMID: 32863996 DOI: 10.5114/aoms.2019.83822] [Reference Citation Analysis]
10 Wu Y, Fu X, Zhu X, He X, Zou C, Han Y, Xu M, Huang C, Lu X, Zhao Y. Prognostic role of systemic inflammatory response in renal cell carcinoma: a systematic review and meta-analysis. J Cancer Res Clin Oncol 2011;137:887-96. [DOI: 10.1007/s00432-010-0951-3] [Cited by in Crossref: 42] [Cited by in F6Publishing: 42] [Article Influence: 3.5] [Reference Citation Analysis]
11 Alt AL, Boorjian SA, Lohse CM, Costello BA, Leibovich BC, Blute ML. Survival after complete surgical resection of multiple metastases from renal cell carcinoma. Cancer. 2011;117:2873-2882. [PMID: 21692048 DOI: 10.1002/cncr.25836] [Cited by in Crossref: 253] [Cited by in F6Publishing: 222] [Article Influence: 23.0] [Reference Citation Analysis]
12 Kramer MW, Merseburger AS, Peters I, Waalkes S, Kuczyk MA. [Systemic and surgical management of metastatic renal cell carcinoma]. Urologe A 2012;51:217-25. [PMID: 22009257 DOI: 10.1007/s00120-011-2713-5] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
13 Tornberg SV, Visapää H, Kilpeläinen TP, Taari K, Järvinen R, Erkkilä K, Nisen H, Järvinen P. Surgery for metastases of renal cell carcinoma: outcome of treatments and preliminary assessment of Leuven-Udine prognostic groups in the targeted therapy era. Scand J Urol 2018;52:419-26. [PMID: 30663485 DOI: 10.1080/21681805.2018.1553893] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
14 Hu Q, Gou Y, Sun C, Ding W, Xu K, Gu B, Xia G, Ding Q. The prognostic value of C-reactive protein in renal cell carcinoma: A systematic review and meta-analysis. Urologic Oncology: Seminars and Original Investigations 2014;32:50.e1-8. [DOI: 10.1016/j.urolonc.2013.07.016] [Cited by in Crossref: 37] [Cited by in F6Publishing: 46] [Article Influence: 4.6] [Reference Citation Analysis]
15 Kirner A, Mayer-Mokler A, Reinhardt C. IMA901: a multi-peptide cancer vaccine for treatment of renal cell cancer. Hum Vaccin Immunother 2014;10:3179-89. [PMID: 25625928 DOI: 10.4161/21645515.2014.983857] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 4.4] [Reference Citation Analysis]
16 Hughes T, Broucek J, Iodice G, Bommareddy PK, Basu S, Kaufman HL. Metastasectomy following incomplete response to high-dose interleukin-2. J Surg Oncol 2018;117:572-8. [DOI: 10.1002/jso.24916] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
17 Tatokoro M, Fujii Y, Kawakami S, Saito K, Koga F, Matsuoka Y, Iimura Y, Masuda H, Kihara K. Phase-II trial of combination treatment of interferon-α, cimetidine, cyclooxygenase-2 inhibitor and renin-angiotensin-system inhibitor (I-CCA therapy) for advanced renal cell carcinoma. Cancer Sci 2011;102:137-43. [PMID: 20973869 DOI: 10.1111/j.1349-7006.2010.01756.x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 1.5] [Reference Citation Analysis]
18 Eggener SE, Yossepowitch O, Kundu S, Motzer RJ, Russo P. Risk score and metastasectomy independently impact prognosis of patients with recurrent renal cell carcinoma. J Urol. 2008;180:873-878; discussion 878. [PMID: 18635225 DOI: 10.1016/j.juro.2008.05.006] [Cited by in Crossref: 91] [Cited by in F6Publishing: 79] [Article Influence: 6.5] [Reference Citation Analysis]
19 Ramez AM, Hamed M, Saad EA. Metastatic renal cell carcinoma to the eyelid: an unusual presentation. Journal of Clinical Urology 2019. [DOI: 10.1177/2051415819827687] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
20 de Martino M, Pantuck AJ, Hofbauer S, Waldert M, Shariat SF, Belldegrun AS, Klatte T. Prognostic impact of preoperative neutrophil-to-lymphocyte ratio in localized nonclear cell renal cell carcinoma. J Urol. 2013;190:1999-2004. [PMID: 23831313 DOI: 10.1016/j.juro.2013.06.082] [Cited by in Crossref: 67] [Cited by in F6Publishing: 66] [Article Influence: 7.4] [Reference Citation Analysis]
21 Zhang C, Pan X, Peng X, Liu K, Wang J, Zhao L, Chen X, Huang G, Li H, Ye J, Lai Y. miR-30b-5p up-regulation related to the dismal prognosis for patients with renal cell cancer. J Clin Lab Anal 2021;35:e23599. [PMID: 33247622 DOI: 10.1002/jcla.23599] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
22 Yasuda Y, Saito K, Yuasa T, Uehara S, Kawamura N, Yokoyama M, Ishioka J, Matsuoka Y, Yamamoto S, Okuno T, Yonese J, Kihara K, Fujii Y. Early response of C-reactive protein as a predictor of survival in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors. Int J Clin Oncol 2017;22:1081-6. [PMID: 28733795 DOI: 10.1007/s10147-017-1166-2] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
23 Ljungberg B. Prognostic markers in renal cell carcinoma. Curr Opin Urol 2007;17:303-8. [PMID: 17762621 DOI: 10.1097/MOU.0b013e328277f180] [Cited by in Crossref: 69] [Cited by in F6Publishing: 23] [Article Influence: 4.6] [Reference Citation Analysis]
24 Schwarz L, Sauvanet A, Regenet N, Mabrut JY, Gigot JF, Housseau E, Millat B, Ouaissi M, Gayet B, Fuks D. Long-term survival after pancreatic resection for renal cell carcinoma metastasis. Ann Surg Oncol. 2014;21:4007-4013. [PMID: 24879589 DOI: 10.1245/s10434-014-3821-4] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 4.0] [Reference Citation Analysis]
25 Tatokoro M, Fujii Y, Kawakami S, Fukui N, Komai Y, Saito K, Koga F, Morimoto S, Fukui I, Kihara K. Favorable response to combination treatment of cimetidine, cyclooxygenase-2 inhibitor and renin-angiotensin system inhibitor in metastatic renal cell carcinoma: Report of three cases: CCA therapy against metastatic RCC. International Journal of Urology 2008;15:848-50. [DOI: 10.1111/j.1442-2042.2008.02102.x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
26 Tatsui CE, Suki D, Rao G, Kim SS, Salaskar A, Hatiboglu MA, Gokaslan ZL, McCutcheon IE, Rhines LD. Factors affecting survival in 267 consecutive patients undergoing surgery for spinal metastasis from renal cell carcinoma. J Neurosurg Spine 2014;20:108-16. [PMID: 24206037 DOI: 10.3171/2013.9.SPINE13158] [Cited by in Crossref: 32] [Cited by in F6Publishing: 13] [Article Influence: 3.6] [Reference Citation Analysis]
27 Tosco L, Van Poppel H, Frea B, Gregoraci G, Joniau S. Survival and impact of clinical prognostic factors in surgically treated metastatic renal cell carcinoma. Eur Urol. 2013;63:646-652. [PMID: 23041360 DOI: 10.1016/j.eururo.2012.09.037] [Cited by in Crossref: 65] [Cited by in F6Publishing: 60] [Article Influence: 6.5] [Reference Citation Analysis]
28 Guzik G. Oncological, surgical and functional results of the treatment of patients after hemipelvectomy due to metastases. BMC Musculoskelet Disord 2018;19:63. [PMID: 29463255 DOI: 10.1186/s12891-018-1979-9] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
29 Shah JB, Margulis V. In search of a better crystal ball: recent advances in prognostic markers for clear-cell renal cell carcinoma. Expert Rev Anticancer Ther 2010;10:837-42. [PMID: 20553209 DOI: 10.1586/era.10.70] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
30 Ishihara H, Takagi T, Kondo T, Fukuda H, Tachibana H, Yoshida K, Iizuka J, Okumi M, Ishida H, Tanabe K. Predictive impact of an early change in serum C-reactive protein levels in nivolumab therapy for metastatic renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations 2020;38:526-32. [DOI: 10.1016/j.urolonc.2019.12.008] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
31 Klatte T, Lam JS, Shuch B, Belldegrun AS, Pantuck AJ. Surveillance for renal cell carcinoma: Why and how? When and how often? Urologic Oncology: Seminars and Original Investigations 2008;26:550-4. [DOI: 10.1016/j.urolonc.2007.05.026] [Cited by in Crossref: 52] [Cited by in F6Publishing: 49] [Article Influence: 3.7] [Reference Citation Analysis]
32 Kloeters C, Mager A, Johannsen M, Ringsdorf M, Roemer A, Tuellmann M, Hamm B, Hein E, Rogalla P. Radiofrequency Ablation of Metastases from Renal Cell Carcinoma: Technique, Complications, and Midterm Outcome. European Urology Supplements 2007;6:653-7. [DOI: 10.1016/j.eursup.2007.03.011] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
33 Zhou L, Cai X, Liu Q, Jian ZY, Li H, Wang KJ. Prognostic Role of C-Reactive Protein In Urological Cancers: A Meta-Analysis. Sci Rep 2015;5:12733. [PMID: 26235332 DOI: 10.1038/srep12733] [Cited by in Crossref: 32] [Cited by in F6Publishing: 36] [Article Influence: 4.6] [Reference Citation Analysis]
34 Henrichs MP, Krebs J, Gosheger G, Streitbuerger A, Nottrott M, Sauer T, Hoell S, Singh G, Hardes J. Modular tumor endoprostheses in surgical palliation of long-bone metastases: a reduction in tumor burden and a durable reconstruction. World J Surg Oncol 2014;12:330. [PMID: 25376274 DOI: 10.1186/1477-7819-12-330] [Cited by in Crossref: 25] [Cited by in F6Publishing: 12] [Article Influence: 3.1] [Reference Citation Analysis]
35 Hsieh PY, Hung SC, Li JR, Wang SS, Yang CK, Chen CS, Lu K, Cheng CL, Chiu KY. The effect of metastasectomy on overall survival in metastatic renal cell carcinoma: A systematic review and meta-analysis. Urol Oncol 2021;39:422-30. [PMID: 33934963 DOI: 10.1016/j.urolonc.2021.02.026] [Reference Citation Analysis]
36 Ali S, Yin-goen Q, Johnson TV, Han W, Johnson NA, Harris WB, Marshall FF, Young AN, Master VA, Osunkoya AO. Expression of C-reactive protein and cyclooxygenase enzyme-2 in clear cell renal cell carcinoma: correlation with pathological parameters in 110 patients. Tumor Biol 2011;32:375-80. [DOI: 10.1007/s13277-010-0130-9] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
37 Naito S, Kinoshita H, Kondo T, Shinohara N, Kasahara T, Saito K, Takayama T, Masumori N, Takahashi W, Takahashi M. Prognostic factors of patients with metastatic renal cell carcinoma with removed metastases: a multicenter study of 556 patients. Urology. 2013;82:846-851. [PMID: 24074981 DOI: 10.1016/j.urology.2013.06.035] [Cited by in Crossref: 44] [Cited by in F6Publishing: 33] [Article Influence: 4.9] [Reference Citation Analysis]
38 Whitson BA, Groth SS, Andrade RS, Garrett L, Dudek AZ, Jessurun J, Maddaus MA. Extension of survival by resection of asynchronous renal cell carcinoma metastases to mediastinal lymph nodes. J Thorac Cardiovasc Surg 2008;135:1022-8. [PMID: 18455579 DOI: 10.1016/j.jtcvs.2007.12.016] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
39 Schmidinger M. Metastasectomy for Metastatic Renal Cell Carcinoma (mRCC): Lucky Break or Evidence-Based Approach? Ann Surg Oncol 2017;24:308-10. [PMID: 27671149 DOI: 10.1245/s10434-016-5592-6] [Reference Citation Analysis]
40 Breau RH, Blute ML. Surgery for renal cell carcinoma metastases. Current Opinion in Urology 2010;20:375-81. [DOI: 10.1097/mou.0b013e32833c7ada] [Cited by in Crossref: 26] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
41 Fujita T, Iwamura M, Ishii D, Tabata K, Matsumoto K, Yoshida K, Baba S. C-reactive protein as a prognostic marker for advanced renal cell carcinoma treated with sunitinib: CRP for sunitinib-treated advanced RCC. International Journal of Urology 2012;19:908-13. [DOI: 10.1111/j.1442-2042.2012.03071.x] [Cited by in Crossref: 38] [Cited by in F6Publishing: 30] [Article Influence: 3.8] [Reference Citation Analysis]
42 Yun ZY, Zhang X, Liu ZP, Liu T, Wang RT, Chen H. Association of decreased mean platelet volume with renal cell carcinoma. Int J Clin Oncol 2017;22:1076-80. [PMID: 28664301 DOI: 10.1007/s10147-017-1158-2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
43 González J, Gaynor JJ, Alameddine M, Esteban M, Ciancio G. Indications, complications, and outcomes following surgical management of locally advanced and metastatic renal cell carcinoma. Expert Rev Anticancer Ther 2018;18:237-50. [PMID: 29353520 DOI: 10.1080/14737140.2018.1431530] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
44 Yamauchi M, Kai K, Shibamiya N, Shimazu R, Monji M, Suzuki K, Kakinoki H, Tobu S, Kuratomi Y. Didactic surgical experience of thyroid metastasis from renal cell carcinoma: A case report. World J Clin Cases 2018; 6(15): 1018-1023 [PMID: 30568957 DOI: 10.12998/wjcc.v6.i15.1018] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
45 Espinoza E, Hassani A, Vaishampayan U, Shi D, Pontes JE, Weaver DW. Surgical excision of duodenal/pancreatic metastatic renal cell carcinoma. Front Oncol 2014;4:218. [PMID: 25177547 DOI: 10.3389/fonc.2014.00218] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
46 Saito K, Tatokoro M, Fujii Y, Iimura Y, Koga F, Kawakami S, Kihara K. Impact of C-Reactive Protein Kinetics on Survival of Patients with Metastatic Renal Cell Carcinoma. European Urology 2009;55:1145-54. [DOI: 10.1016/j.eururo.2008.10.012] [Cited by in Crossref: 87] [Cited by in F6Publishing: 82] [Article Influence: 6.7] [Reference Citation Analysis]
47 Teishima J, Kobatake K, Kitano H, Nagamatsu H, Sadahide K, Hieda K, Shinmei S, Shoji K, Inoue S, Hayashi T, Inoue Y, Ohara S, Mita K, Matsubara A. The impact of change in serum C-reactive protein level on the prediction of effects of molecular targeted therapy in patients with metastatic renal cell carcinoma. BJU Int 2016;117:E67-74. [DOI: 10.1111/bju.13260] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 2.4] [Reference Citation Analysis]
48 Ishihara H, Takagi T, Kondo T, Fukuda H, Tachibana H, Yoshida K, Iizuka J, Kobayashi H, Ishida H, Tanabe K. Prognostic impact of metastasectomy in renal cell carcinoma in the postcytokine therapy era. Urol Oncol 2021;39:77.e17-25. [PMID: 32863124 DOI: 10.1016/j.urolonc.2020.08.011] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
49 Joshi S, Eldefrawy A, Ciancio G. 8-year survival in a patient with several recurrences of renal cell carcinoma after radical nephrectomy. Cent European J Urol. 2012;65:242-243. [PMID: 24578974 DOI: 10.5173/ceju.2012.04.art16] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.1] [Reference Citation Analysis]
50 Russell CM, Espiritu PN, Kassouf W, Schwaab T, Buethe DD, Dhilon J, Sexton WJ, Poch M, Powsang JM, Tanguay S, Nayan M, Alsaadi H, Hanzly MI, Spiess PE. Surgical Outcomes in the Management of Isolated Nodal Recurrences: A Multicenter, International Retrospective Cohort. Journal of Urology 2014;192:350-6. [DOI: 10.1016/j.juro.2014.02.010] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.9] [Reference Citation Analysis]
51 Rendon RA, Kapoor A, Breau R, Leveridge M, Feifer A, Black PC, So A. Surgical management of renal cell carcinoma: Canadian Kidney Cancer Forum Consensus. Can Urol Assoc J 2014;8:E398-412. [PMID: 25024794 DOI: 10.5489/cuaj.1894] [Cited by in Crossref: 17] [Cited by in F6Publishing: 22] [Article Influence: 2.1] [Reference Citation Analysis]
52 Calabrò F, Sternberg CN. Is there a role for presurgical therapy for renal cell carcinoma? Expert Review of Anticancer Therapy 2014;10:807-12. [DOI: 10.1586/era.10.14] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
53 Saito K, Kihara K. Role of C-reactive protein in urological cancers: a useful biomarker for predicting outcomes. Int J Urol 2013;20:161-71. [PMID: 22897628 DOI: 10.1111/j.1442-2042.2012.03121.x] [Cited by in Crossref: 39] [Cited by in F6Publishing: 38] [Article Influence: 3.9] [Reference Citation Analysis]
54 Shrotriya S, Walsh D, Bennani-Baiti N, Thomas S, Lorton C. C-Reactive Protein Is an Important Biomarker for Prognosis Tumor Recurrence and Treatment Response in Adult Solid Tumors: A Systematic Review. PLoS One 2015;10:e0143080. [PMID: 26717416 DOI: 10.1371/journal.pone.0143080] [Cited by in Crossref: 113] [Cited by in F6Publishing: 116] [Article Influence: 16.1] [Reference Citation Analysis]
55 Berger A, Aron M, Canes D, Gill IS. Laparoscopic management of interaortocaval metastases of renal cell carcinoma. J Endourol 2008;22:2381-4; discussion 2384. [PMID: 18937601 DOI: 10.1089/end.2008.0160] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
56 Fukushima H, Hozumi T, Goto T, Nihei K, Karasawa K, Nakanishi Y, Kataoka M, Tobisu K, Koga F. Prognostic significance of intensive local therapy to bone lesions in renal cell carcinoma patients with bone metastasis. Clin Exp Metastasis 2016;33:699-705. [PMID: 27316704 DOI: 10.1007/s10585-016-9805-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
57 Zaid HB, Parker WP, Safdar NS, Gershman B, Erwin PJ, Murad MH, Boorjian SA, Costello BA, Thompson RH, Leibovich BC. Outcomes Following Complete Surgical Metastasectomy for Patients with Metastatic Renal Cell Carcinoma: A Systematic Review and Meta-Analysis. J Urol. 2017;197:44-49. [PMID: 27473875 DOI: 10.1016/j.juro.2016.07.079] [Cited by in Crossref: 57] [Cited by in F6Publishing: 51] [Article Influence: 9.5] [Reference Citation Analysis]
58 Le Mouel S, Gaston A, Paule B. [The role of surgery in bone metastases of renal cell carcinoma: 13 case reports]. Prog Urol 2008;18:1045-9. [PMID: 19041809 DOI: 10.1016/j.purol.2008.08.004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
59 Procopio G, Apollonio G, Cognetti F, Miceli R, Milella M, Mosca A, Chiuri VE, Bearz A, Morelli F, Ortega C, Atzori F, Donini M, Ratta R, Raimondi A, Claps M, Martinetti A, Capitanio U, de Braud FG, Cappelletti V, Verzoni E. Sorafenib Versus Observation Following Radical Metastasectomy for Clear-cell Renal Cell Carcinoma: Results from the Phase 2 Randomized Open-label RESORT Study. Eur Urol Oncol. 2019;2:699-707. [PMID: 31542243 DOI: 10.1016/j.euo.2019.08.011] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
60 Chung SD, Chu SH, Tsai CC. Re: Capitanio et al.: Cytoreductive partial nephrectomy does not undermine cancer control in metastatic renal cell carcinoma: a population-based study. (Urology 2008;72:1090-1095). Urology 2009;73:682-3; author reply 683-4. [PMID: 19248907 DOI: 10.1016/j.urology.2008.11.044] [Reference Citation Analysis]
61 Xiong Y, Liu L, Wang J, Xi W, Xia Y, Bai Q, Qu Y, Long Q, Xu J, Guo J. Low CCL-21 expression associates with unfavorable postoperative prognosis of patients with metastatic renal cell carcinoma. Oncotarget 2017;8:25650-9. [PMID: 27783999 DOI: 10.18632/oncotarget.12827] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
62 May M, Brookman-Amissah S, Pflanz S, Knoll N, Roigas J, Gunia S, Hoschke B, Kendel F. [Value of the postoperative Störkel score. Predict disease-free survival of patients with surgically resected renal cell carcinoma]. Urologe A 2009;48:284-90. [PMID: 19104768 DOI: 10.1007/s00120-008-1912-1] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
63 Zhang N, Zhang H, Zhu D, JiRiGaLa, Yu D, Wang C, WuYunBiLiGe, Amin, ZhiHong, Yu H, Chen X, Wang M. Prognostic role of pretreatment lactate dehydrogenase in patients with metastatic renal cell carcinoma: A systematic review and meta-analysis. Int J Surg 2020;79:66-73. [PMID: 32417461 DOI: 10.1016/j.ijsu.2020.05.019] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
64 Saito K, Kihara K. C-reactive protein as a biomarker for urological cancers. Nat Rev Urol 2011;8:659-66. [DOI: 10.1038/nrurol.2011.145] [Cited by in Crossref: 65] [Cited by in F6Publishing: 58] [Article Influence: 5.9] [Reference Citation Analysis]
65 Wood CG, Margulis V. Neoadjuvant (presurgical) therapy for renal cell carcinoma: a new treatment paradigm for locally advanced and metastatic disease. Cancer 2009;115:2355-60. [PMID: 19402066 DOI: 10.1002/cncr.24240] [Cited by in Crossref: 48] [Cited by in F6Publishing: 41] [Article Influence: 3.7] [Reference Citation Analysis]
66 Apollonio G, Raimondi A, Verzoni E, Claps M, Sepe P, Pagani F, Ratta R, Montorsi F, De Braud FGM, Procopio G. The role of metastasectomy in advanced renal cell carcinoma. Expert Review of Anticancer Therapy 2019;19:603-11. [DOI: 10.1080/14737140.2019.1625772] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
67 Saito K, Kihara K. Role of C-reactive protein as a biomarker for renal cell carcinoma. Expert Rev Anticancer Ther 2010;10:1979-89. [PMID: 21110763 DOI: 10.1586/era.10.192] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 2.6] [Reference Citation Analysis]
68 Ismail I, Neuen BL, Mantha M. Solitary jejunal metastasis from renal cell carcinoma presenting as small bowel obstruction 19 years after nephrectomy. BMJ Case Rep 2015;2015:bcr2015210857. [PMID: 26370628 DOI: 10.1136/bcr-2015-210857] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
69 Cochran DC, Chan MD, Aklilu M, Lovato JF, Alphonse NK, Bourland JD, Urbanic JJ, McMullen KP, Shaw EG, Tatter SB, Ellis TL. The effect of targeted agents on outcomes in patients with brain metastases from renal cell carcinoma treated with Gamma Knife surgery. J Neurosurg 2012;116:978-83. [PMID: 22385005 DOI: 10.3171/2012.2.JNS111353] [Cited by in Crossref: 57] [Cited by in F6Publishing: 28] [Article Influence: 5.7] [Reference Citation Analysis]
70 Kim SH, Seo SI, Lee HM, Choi HY, Jeon SH, Lee HL, Kwon TG, Kim YJ, Kim WJ, Chung J. A Prospective Multicenter Trial of the Efficacy and Tolerability of Neoadjuvant Sunitinib for Inoperable Metastatic Renal Cell Carcinoma. J Korean Med Sci 2016;31:1983-8. [PMID: 27822939 DOI: 10.3346/jkms.2016.31.12.1983] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
71 Schmidinger M. Improving outcomes in metastatic clear cell renal cell carcinoma by sequencing therapy. Am Soc Clin Oncol Educ Book 2014;:e228-38. [PMID: 24857107 DOI: 10.14694/EdBook_AM.2014.34.e228] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]